Should You Continue to Hold DGX Stock in Your Portfolio?

Core Insights - Quest Diagnostics (DGX) is positioned for growth due to investments in advanced diagnostics and innovative services, despite concerns over a debt-laden balance sheet and macroeconomic pressures [1] Financial Performance - Over the past year, Quest Diagnostics stock has increased by 16.5%, outperforming the industry growth of 8.2% and the S&P 500's rise of 23.2% [2] - The company has a market capitalization of $21.89 billion and an earnings yield of 5.32% [2] - Quest Diagnostics has consistently surpassed earnings estimates in the last four quarters, with an average surprise of 2.83% [2] Growth Drivers - The company focuses on five major clinical areas: advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health, which are expected to drive growth [3] - The AD-Detect blood test portfolio for Alzheimer's disease experienced double-digit growth in Q4 2025, supported by increased provider adoption [3] - In oncology, Quest Diagnostics is enhancing its presence in blood-based minimal residual disease (MRD) testing and received FDA breakthrough device designation for its Haystack MRD test [4] Acquisition Strategy - Quest Diagnostics aims to generate growth through strategically aligned acquisitions, having completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories in 2025 [5] - In 2024, the company closed eight acquisitions, including LifeLabs, which expanded its presence in Canada [6] Operational Excellence - The company achieved its target of 3% annual cost savings and productivity improvements through the Invigorate cost-savings program in 2025 [6] - Quest Diagnostics employs automation and AI technologies to enhance quality, service, efficiency, and workforce experience [9] Debt and Economic Challenges - As of Q4 2025, Quest Diagnostics had long-term debt of $5.17 billion, with cash and cash equivalents at $420 million [11] - The evolving U.S. healthcare system presents risks, including reduced utilization and reimbursement from government payers, which may impact the company's operations [12] Future Outlook - The Zacks Consensus Estimate for Quest Diagnostics' 2026 earnings per share (EPS) has increased by 1.8% to $10.60, with a revenue estimate of $11.75 billion, indicating a 6.5% growth from the previous year [13]